First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
Mak LY, Wong DKH, Cheung KS, et al
BMC Gastroenterology|March 24, 2021
NEXT
Journal Summary
This study was undertaken to investigate the profiles of serum hepatitis B core-related antigen (HBcrAg) in chronic hepatitis B (CHB) patients treated with first-line nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF). Researchers assessed serum HBcrAg in 120 treatment-naïve CHB patients receiving one of the 3 NAs (ETV: TDF: TAF = 60: 26: 34) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan). They evaluated serum HBcrAg levels at week 0, week 48, and week 96 of NA therapy. Although HBcrAg reduction was numerically greater in the tenofovir-treated group, the magnitude of reduction of HBcrAg levels after a 2-year first-line treatment did not differ statistically among the current first-line NAs. Future long-term trials are needed to ascertain if tenofovir exerts a more pronounced effect on HBcrAg.
Read the full article on BMC Gastroenterology.作者: StephenW 时间: 2021-3-25 17:05